Sundararaman Swaminathan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sundararaman Swaminathan has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Aarti Sharma
Mayo Clinic Arizona USA; Department of Nephrology, Indian Institute of Science, Bengaluru, Karnataka, India
2 shared publications Latha Pathangey
Mayo Clinic Arizona USA
2 shared publicationsSinto Sebastian Chirackal
Division of Hematology and Medical Oncology, Mayo Clinic Phoenix, AZ, USA
2 shared publicationsAkhilesh Pandey
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA; Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ, USA; Manipal Academy of Higher Education, Manipal, Karnataka, India; Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA
1 shared publication- Alyssa Bishop
Division of Information Technology, Mayo Clinic, Rochester, MN, United States
1 shared publication - Arvind Kumar Garg
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, LaCrosse, WI, United States
1 shared publication
Latest Publications
- Open Access
- 23 December 2025
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (1) , 106233
Mechanistic insights into the antiproliferative effect of the redox-active iron chelator Dp44mT on multiple myeloma cell lines
- 23 December 2025
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 48 (1) , 106233
Open AccessMechanistic insights into the antiproliferative effect of the redox-active iron chelator Dp44mT on multiple myeloma cell lines
- 21 December 2025
- Published by Wiley in European Journal of Haematology
- Vol. 116 (4) , 391-401
Ferritin H Knockout Induces Differential Immunomodulatory Drug Responses in Multiple Myeloma Cell Lines
Background: Immunomodulatory agents (IMiDs) are a cornerstone in the successful management of multiple myeloma (MM). However, acquired IMiD resistance leading to disease relapses remains a major barrier. Hydrogen peroxide generation and oxidative stress are key mediators that determine IMiD's effectiveness in MM. Iron plays a key role in the generation of oxidative stress; therefore, cellular iron levels are tightly governed. FTH1 is the major iron storage protein that tightly regulates cellular iron availability. Hence, the present study is targeted to investigate the role of FTH1 in MM and IMiD resistance. Methods: IMiD‐sensitive and IMiD‐resistant MM cells were analyzed for expression of iron‐metabolism genes. CRISPR‐cas9‐mediated knockout of FTH1 was performed and the after‐effects were assessed through multiple experiments. Results: Initial analysis showed a positive correlation between FTH1 expression and IMiD resistance in MM cells. FTH1 ‐KO reduced IMiD sensitivity in the KMS11 cell line but had no effect on the RPMI8226 cell line. RNA‐seq data showed downregulation of ER‐stress and calcium signaling genes after FTH1 ‐KO. Further, KMS11‐ FTH1 KO cells exhibited lower intracellular ROS, labile‐iron, and mitochondrial superoxide levels along with increased CD63, suggesting activation of L‐ferritin secretory pathways. Conclusion: Data reveals a link between FTH1 , labile iron, ROS, and IMiD resistance in MM cells.
- 21 December 2025
- Published by Wiley in European Journal of Haematology
- Vol. 116 (4) , 391-401
Ferritin H Knockout Induces Differential Immunomodulatory Drug Responses in Multiple Myeloma Cell Lines
Background: Immunomodulatory agents (IMiDs) are a cornerstone in the successful management of multiple myeloma (MM). However, acquired IMiD resistance leading to disease relapses remains a major barrier. Hydrogen peroxide generation and oxidative stress are key mediators that determine IMiD's effectiveness in MM. Iron plays a key role in the generation of oxidative stress; therefore, cellular iron levels are tightly governed. FTH1 is the major iron storage protein that tightly regulates cellular iron availability. Hence, the present study is targeted to investigate the role of FTH1 in MM and IMiD resistance. Methods: IMiD‐sensitive and IMiD‐resistant MM cells were analyzed for expression of iron‐metabolism genes. CRISPR‐cas9‐mediated knockout of FTH1 was performed and the after‐effects were assessed through multiple experiments. Results: Initial analysis showed a positive correlation between FTH1 expression and IMiD resistance in MM cells. FTH1 ‐KO reduced IMiD sensitivity in the KMS11 cell line but had no effect on the RPMI8226 cell line. RNA‐seq data showed downregulation of ER‐stress and calcium signaling genes after FTH1 ‐KO. Further, KMS11‐ FTH1 KO cells exhibited lower intracellular ROS, labile‐iron, and mitochondrial superoxide levels along with increased CD63, suggesting activation of L‐ferritin secretory pathways. Conclusion: Data reveals a link between FTH1 , labile iron, ROS, and IMiD resistance in MM cells.
- Open Access
- 8 September 2025
- Published by Association for Computing Machinery (ACM)
- p. 30-45
DPUF: DPU-accelerated Near-storage Secure Filtering
- 8 September 2025
- Published by Association for Computing Machinery (ACM)
- p. 30-45
Open AccessDPUF: DPU-accelerated Near-storage Secure Filtering
- Open Access
- 20 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 5152
Immune Checkpoint Inhibitors and Allograft Rejection Risk: Emerging Evidence Regarding Their Use in Kidney Transplant Recipients
The indications for immune checkpoint inhibitor (ICI) use in cancer treatment continue to expand. This is attributable to their proven anticancer activity in addition to their tolerability and favorable toxicity profile as compared to conventional chemotherapeutic agents. ICIs work by blocking the inhibitory signals between tumor cells and T-cells, thereby enhancing the T-cell cytotoxic activity to inhibit tumor growth. Because of their immune-stimulating effect, ICIs are linked to adverse renal outcomes in both native and transplanted kidneys. The risk of kidney allograft rejection in the setting of ICI use has been reported to be around 40%, leading to an increased risk of graft loss. In this report, we review the literature examining outcomes in kidney transplant recipients receiving ICIs for various oncologic indications.
- 20 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (14) , 5152
Open AccessImmune Checkpoint Inhibitors and Allograft Rejection Risk: Emerging Evidence Regarding Their Use in Kidney Transplant Recipients
The indications for immune checkpoint inhibitor (ICI) use in cancer treatment continue to expand. This is attributable to their proven anticancer activity in addition to their tolerability and favorable toxicity profile as compared to conventional chemotherapeutic agents. ICIs work by blocking the inhibitory signals between tumor cells and T-cells, thereby enhancing the T-cell cytotoxic activity to inhibit tumor growth. Because of their immune-stimulating effect, ICIs are linked to adverse renal outcomes in both native and transplanted kidneys. The risk of kidney allograft rejection in the setting of ICI use has been reported to be around 40%, leading to an increased risk of graft loss. In this report, we review the literature examining outcomes in kidney transplant recipients receiving ICIs for various oncologic indications.
- Open Access
- 1 May 2024
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 12, e50164
An Electronic Health Record–Integrated Application for Standardizing Care and Monitoring Patients With Autosomal Dominant Polycystic Kidney Disease Enrolled in a Tolvaptan Clinic: Design and Implementation Study
Background: Tolvaptan is the only US Food and Drug Administration–approved drug to slow the progression of autosomal dominant polycystic kidney disease (ADPKD), but it requires strict clinical monitoring due to potential serious adverse events. Objective: We aimed to share our experience in developing and implementing an electronic health record (EHR)–based application to monitor patients with ADPKD who were initiated on tolvaptan. Methods: The application was developed in collaboration with clinical informatics professionals based on our clinical protocol with frequent laboratory test monitoring to detect early drug-related toxicity. The application streamlined the clinical workflow and enabled our nursing team to take appropriate actions in real time to prevent drug-related serious adverse events. We retrospectively analyzed the characteristics of the enrolled patients. Results: As of September 2022, a total of 214 patients were enrolled in the tolvaptan program across all Mayo Clinic sites. Of these, 126 were enrolled in the Tolvaptan Monitoring Registry application and 88 in the Past Tolvaptan Patients application. The mean age at enrollment was 43.1 (SD 9.9) years. A total of 20 (9.3%) patients developed liver toxicity, but only 5 (2.3%) had to discontinue the drug. The 2 EHR-based applications allowed consolidation of all necessary patient information and real-time data management at the individual or population level. This approach facilitated efficient staff workflow, monitoring of drug-related adverse events, and timely prescription renewal. Conclusions: Our study highlights the feasibility of integrating digital applications into the EHR workflow to facilitate efficient and safe care delivery for patients enrolled in a tolvaptan program. This workflow needs further validation but could be extended to other health care systems managing chronic diseases requiring drug monitoring.
- 1 May 2024
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 12, e50164
Open AccessAn Electronic Health Record–Integrated Application for Standardizing Care and Monitoring Patients With Autosomal Dominant Polycystic Kidney Disease Enrolled in a Tolvaptan Clinic: Design and Implementation Study
Background: Tolvaptan is the only US Food and Drug Administration–approved drug to slow the progression of autosomal dominant polycystic kidney disease (ADPKD), but it requires strict clinical monitoring due to potential serious adverse events. Objective: We aimed to share our experience in developing and implementing an electronic health record (EHR)–based application to monitor patients with ADPKD who were initiated on tolvaptan. Methods: The application was developed in collaboration with clinical informatics professionals based on our clinical protocol with frequent laboratory test monitoring to detect early drug-related toxicity. The application streamlined the clinical workflow and enabled our nursing team to take appropriate actions in real time to prevent drug-related serious adverse events. We retrospectively analyzed the characteristics of the enrolled patients. Results: As of September 2022, a total of 214 patients were enrolled in the tolvaptan program across all Mayo Clinic sites. Of these, 126 were enrolled in the Tolvaptan Monitoring Registry application and 88 in the Past Tolvaptan Patients application. The mean age at enrollment was 43.1 (SD 9.9) years. A total of 20 (9.3%) patients developed liver toxicity, but only 5 (2.3%) had to discontinue the drug. The 2 EHR-based applications allowed consolidation of all necessary patient information and real-time data management at the individual or population level. This approach facilitated efficient staff workflow, monitoring of drug-related adverse events, and timely prescription renewal. Conclusions: Our study highlights the feasibility of integrating digital applications into the EHR workflow to facilitate efficient and safe care delivery for patients enrolled in a tolvaptan program. This workflow needs further validation but could be extended to other health care systems managing chronic diseases requiring drug monitoring.